Clinical Ward of Breast Cancer and Reconstructive Surgery, Oncology Centre Prof. F. Łukaszczyk Memorial Hospital, Bydgoszcz, Poland.
Department of Pathophysiology, Faculty of Pharmacy, Nicolaus Copernicus University Toruń, Collegium Medicum in Bydgoszcz, Poland
Biosci Rep. 2018 Mar 29;38(2). doi: 10.1042/BSR20171657. Print 2018 Apr 27.
Thrombosis is one of the leading causes of mortality in cancer patients. The aim of the study was to evaluate the concentrations and activities of selected haemostatic parameters in the plasma of patients diagnosed with breast cancer (BrCa) and to make an attempt at finding associations with their levels and selected clinicopathological factors; clinical classification, histological grading, and molecular subtype of BrCa. The study involved 145 Caucasian ethnicity women. Eighty-five women aged 45-66 with primary BrCa without distant metastases (M0). Inclusion criteria were as follows: histopathological examination confirming the diagnosis of primary BrCa, without previous radiotherapy and chemotherapy. The control group consisted of 60, post-menopausal women, aged 45-68. Haemostatic profile expressed by concentrations and activities of tissue factor (TF) and its inhibitor (TFPI) as well as concentrations of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) were measured applying immunoassay techniques. A significantly higher concentration of PAI-1 was noted in patients with BrCa localized in the left breast. We observed significantly lower activity of TFPI and significantly higher concentration of PAI-1 in the group of patients with invasive ductal carcinoma as compared with invasive lobular carcinoma. A significantly higher concentration of t-PA in patients with pT2 BrCa in relation to pT1 cases was noted. Based on comprehensive analysis of haemostatic profile depending on clinicopathological features, we suggest that haemostatic parameters play crucial roles in invasion and metastases of malignant tumours.
血栓形成是癌症患者死亡的主要原因之一。本研究的目的是评估诊断为乳腺癌 (BrCa) 患者血浆中选定止血参数的浓度和活性，并尝试寻找其水平与所选临床病理因素之间的关联；BrCa 的临床分类、组织学分级和分子亚型。该研究涉及 145 名白种人女性。85 名年龄在 45-66 岁之间、无远处转移 (M0) 的原发性 BrCa 女性。纳入标准如下：组织病理学检查证实原发性 BrCa 诊断，无先前的放疗和化疗。对照组由 60 名绝经后女性组成，年龄在 45-68 岁之间。采用免疫测定技术测量组织因子 (TF) 及其抑制剂 (TFPI) 的浓度和活性以及组织纤溶酶原激活物 (t-PA) 和纤溶酶原激活物抑制剂 1 (PAI-1) 的浓度来表示止血谱。左侧乳房局部乳腺癌患者的 PAI-1 浓度明显较高。与浸润性小叶癌相比，浸润性导管癌患者的 TFPI 活性显著降低，PAI-1 浓度显著升高。与 pT1 病例相比，pT2 BrCa 患者的 t-PA 浓度明显升高。基于根据临床病理特征对止血谱进行综合分析，我们认为止血参数在恶性肿瘤的侵袭和转移中起关键作用。
